Home 
Acta Virologica 2023 Acta Virologica Vol.67, No.1, p. 51 – 58, 2023
Acta Virologica 2023 Acta Virologica Vol.67, No.1, p. 51 – 58, 2023
Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Current articles 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Acta Virologica Vol.67, No.1, p. 51 – 58, 2023 |
||
| Title: Notoginsenoside R1 inhibits hepatitis B virus replication by modulating SIRT1 activity | ||
| Author: Wujing Zhang, Jingjing Cui, Lichun Li, Lijuan Chai, Qingling Hou, Huaqi Yu | ||
| Abstract: The hepatitis B virus (HBV) infection remains highly prevalent globally. The present study aimed to explore the possible therapeutic effect of notoginsenoside R1, which has attracted considerable attention due to its diverse pharmacological effects, on HBV infection. The HBV-containing hepatocellular carcinoma cell lines, HepG2 and MHCC97H, were used in this study. We first treated the two cell lines with different concentrations of notoginsenoside R1 and subsequently measured the relative levels of HBV DNA, HBV surface antigen, HBV core antigen, and sirtuin 1 (SIRT1) using reverse transcription-quantitative polymerase chain reaction and western blotting. Finally, an HBV hemodynamic replication model was created to test the effect of notoginsenoside R1 on HBV replication. Notoginsenoside R1 inhibited the replication of HBV. This inhibitory effect was mediated through the downregulation of SIRT1 activity. Additionally, the inhibition of SIRT1 activity by silencing its expression or treatment with the SIRT1 inhibitor, selisistat, suppressed HBV replication. Furthermore, our animal experiments demonstrated that notoginsenoside R1 was effective at suppressing HBV replication in vivo. Thus, notoginsenoside R1 suppresses HBV replication by downregulating SIRT1 activity in vitro and in vivo. |
||
| Keywords: notoginsenoside R1; hepatitis B virus; SIRT1 | ||
| Published online: 22-Mar-2023 | ||
| Year: 2023, Volume: 67, Issue: 1 | Page From: 51, Page To: 58 | |
| doi:10.4149/av_2023_105 |
||
|
|
 download file |
|